Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
US-9803224-B2 · Oct 31, 2017 · US
US9932613B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9932613-B2 |
| Application number | US-201715792446-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 24, 2017 |
| Priority date | May 11, 2012 |
| Publication date | Apr 3, 2018 |
| Grant date | Apr 3, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Opening claim text (preview).
What is claimed is: 1. An engineered polynucleotide encoding an engineered polypeptide having imine reductase activity, wherein said polypeptide has at least 90% sequence identity to the polypeptide of SEQ ID NO: 2, and comprises a substitution at a position corresponding to position 280 of SEQ ID NO: 2, wherein the amino acid at position 280 has been replaced with an aliphatic or non-polar residue. 2. The engineered polynucleotide of claim 1 , wherein said polypeptide has at least 90% sequence identity to the polypeptide of SEQ ID NO: 2, wherein the amino acid at the position corresponding to position 280 of SEQ ID NO: 2 has been replaced with leucine. 3. The engineered polynucleotide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1a) pyruvate, and substrate compound (2b) butylamine to product compound (3b), N-2-(butylamino)propanoic acid, under suitable reaction conditions. 4. The engineered polynucleotide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone, and substrate compound (2a) L-norvaline to product compound (3c), (S)-2-(cyclohexylamino)pentanoic acid, under suitable reaction conditions. 5. The engineered polynucleotide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1b) cyclohexanone, and substrate compound (2b) butylamine to product compound (3d), N-butylcyclohexanamine, under suitable reaction conditions. 6. The engineered polynucleotide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1i), and substrate compound (2b) to product compound (3n), under suitable reaction conditions. 7. The engineered polynucleotide of claim 1 , wherein said polypeptide is capable of converting substrate compound (1j), and substrate compound (2b) to product compound (3o), under suitable reaction conditions.
Amines; Imines · CPC title
Heterocyclic compounds containing sulfur atoms as ring hetero atoms in the condensed system (cepam nucleus C12P35/00; penam nucleus C12P37/00) · CPC title
Amides, e.g. chloramphenicol {or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes (peptides C12P21/00 or C07K)} · CPC title
Alanine; Leucine; Isoleucine; Serine; Homoserine · CPC title
Tauropine dehydrogenase (1.5.1.23) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.